Kakhki F, Sargazi S, Montazerifar F, Majidpour M, Karajibani A, Karajibani M
J Clin Lab Anal. 2024; 38(5):e25021.
PMID: 38468402
PMC: 10959184.
DOI: 10.1002/jcla.25021.
Alrashid M, Al-Serri A, Hussain R, Al-Bustan S, Al-Barrak J
Biomedicines. 2023; 11(12).
PMID: 38137390
PMC: 10740888.
DOI: 10.3390/biomedicines11123166.
Zhang N, Sun Y, Wang T, Xu X, Cao M
Front Oncol. 2022; 12:974939.
PMID: 36185210
PMC: 9515549.
DOI: 10.3389/fonc.2022.974939.
Gligorijevic N, Dobrijevic Z, Sunderic M, Robajac D, cetic D, Penezic A
Life (Basel). 2022; 12(8).
PMID: 36013453
PMC: 9410426.
DOI: 10.3390/life12081274.
Wang S, Chi K, Wu D, Hong Q
Front Pharmacol. 2022; 12:807119.
PMID: 35002740
PMC: 8728008.
DOI: 10.3389/fphar.2021.807119.
Uniportal video-assisted thoracic surgery for major lung resection is associated with less immunochemokine disturbances than multiportal approach.
Yu P, Chan K, Lau R, Wan I, Chen G, Ng C
Sci Rep. 2021; 11(1):10369.
PMID: 33990645
PMC: 8121796.
DOI: 10.1038/s41598-021-89598-2.
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Li T, Wu S, Jia L, Cao W, Yao Y, Zhao G
Cancer Biol Med. 2020; 17(2):357-370.
PMID: 32587774
PMC: 7309472.
DOI: 10.20892/j.issn.2095-3941.2019.0107.
Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu S, Nadesan P, Puviindran V, Stallcup W, Kirsch D, Alman B
J Biol Chem. 2017; 293(7):2466-2475.
PMID: 29196603
PMC: 5818183.
DOI: 10.1074/jbc.M117.805051.
Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma.
Luo L, Zhao L, Wang Y, Tian X, Xi M, Shen J
Sci Rep. 2015; 5:17336.
PMID: 26670461
PMC: 4680797.
DOI: 10.1038/srep17336.
Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer.
Du Y, Long Q, Shi Y, Liu X, Li X, Zeng J
Oncol Rep. 2015; 34(5):2273-81.
PMID: 26323436
PMC: 4583521.
DOI: 10.3892/or.2015.4201.
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?.
Zielinska H, Bahl A, Holly J, Perks C
Breast Cancer (Dove Med Press). 2015; 7:9-19.
PMID: 25632238
PMC: 4304531.
DOI: 10.2147/BCTT.S43932.
Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage.
Chua M, Lin M, Martin J, Baxter R
J Cell Commun Signal. 2015; 9(2):167-76.
PMID: 25617051
PMC: 4458249.
DOI: 10.1007/s12079-015-0262-1.
Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.
Muc-Wierzgon M, Nowakowska-Zajdel E, Dziegielewska-Gesiak S, Kokot T, Klakla K, Fatyga E
World J Gastroenterol. 2014; 20(29):9759-74.
PMID: 25110413
PMC: 4123364.
DOI: 10.3748/wjg.v20.i29.9759.
IGF binding proteins in cancer: mechanistic and clinical insights.
Baxter R
Nat Rev Cancer. 2014; 14(5):329-41.
PMID: 24722429
DOI: 10.1038/nrc3720.
CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing.
Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H
Oncogene. 2013; 34(1):104-18.
PMID: 24292684
DOI: 10.1038/onc.2013.522.
The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome.
Muhidin S, Magan A, Osman K, Syed S, Ahmed M
J Obes. 2013; 2012:637538.
PMID: 23304464
PMC: 3523590.
DOI: 10.1155/2012/637538.
Intrinsic, Pro-Apoptotic Effects of IGFBP-3 on Breast Cancer Cells are Reversible: Involvement of PKA, Rho, and Ceramide.
Perks C, Burrows C, Holly J
Front Endocrinol (Lausanne). 2012; 2:13.
PMID: 22654794
PMC: 3356103.
DOI: 10.3389/fendo.2011.00013.
IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors.
Regel I, Eichenmuller M, Joppien S, Liebl J, Haberle B, Muller-Hocker J
Mol Cancer. 2012; 11:9.
PMID: 22401581
PMC: 3349592.
DOI: 10.1186/1476-4598-11-9.
Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma.
Zhao L, He L, Zhang R, Cai M, Liao Y, Qian D
Med Oncol. 2011; 29(4):2669-76.
PMID: 22167391
DOI: 10.1007/s12032-011-0133-4.
Insulin resistance and hyperinsulinaemia in the development and progression of cancer.
Godsland I
Clin Sci (Lond). 2009; 118(5):315-32.
PMID: 19922415
PMC: 2782313.
DOI: 10.1042/CS20090399.